Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study

Br J Cancer. 2021 Aug;125(3):466. doi: 10.1038/s41416-021-01447-1.

Michael Guenther^#¹, Michael Haas², Volker Heinemann^{2

3}, Stephan Kruger², Christoph Benedikt Westphalen², Michael von Bergwelt-Baildon^{2

3}, Julia Mayerle⁴, Jens Werner⁵, Thomas Kirchner^{1

3}, Stefan Boeck^#^{2

3}, Steffen Ormanns^#⁶

¹ Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.
² Department of Internal Medicine III, Grosshadern University Hospital, Ludwig-Maximilians-University, Munich, Germany.
³ German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.
⁴ Department of Internal Medicine II, Grosshadern University Hospital, Ludwig-Maximilians-University, Munich, Germany.
⁵ Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians-University, Munich, Germany.
⁶ Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany. steffen.ormanns@med.uni-muenchen.de.

^# Contributed equally.

No abstract available

Publication types